IMMUNE THROMBOCYTOPENIC PURPURA (ITP)
Clinical trials for IMMUNE THROMBOCYTOPENIC PURPURA (ITP) explained in plain language.
Never miss a new study
Get alerted when new IMMUNE THROMBOCYTOPENIC PURPURA (ITP) trials appear
Sign up with your email to follow new studies for IMMUNE THROMBOCYTOPENIC PURPURA (ITP), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New shot shows promise for Long-Term control of bleeding disorder
Disease control Recruiting nowThis study tests the long-term safety of a drug called mezagitamab for adults with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing easy bruising and bleeding. About 150 participants who completed earlier mezagitamab studies w…
Matched conditions: IMMUNE THROMBOCYTOPENIC PURPURA (ITP)
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New hope for teens with rare bleeding disorder: experimental drug enters final testing
Disease control Recruiting nowThis study tests an IV drug called efgartigimod in teens aged 12 to 18 with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bruising and bleeding. The goal is to find the right dose and see if it safely raises platelet counts…
Matched conditions: IMMUNE THROMBOCYTOPENIC PURPURA (ITP)
Phase: PHASE2, PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New injection aims to stabilize platelets in chronic ITP patients
Disease control Recruiting nowThis Phase 3 trial tests whether mezagitamab, given as a shot under the skin, can safely keep platelet counts stable in adults with chronic ITP. ITP is a condition where the immune system destroys platelets, leading to easy bruising and bleeding. The study will compare mezagitama…
Matched conditions: IMMUNE THROMBOCYTOPENIC PURPURA (ITP)
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC